Flumazenil for Benzodiazepine Reversal in Electroconvulsive Therapy (FLEET): A Randomized Controlled Trial

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-522506-20-00

Enrollment

145

Registered

2025-09-09

Start date

Unknown

Completion date

Unknown

Last updated

2025-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

Objective cognitive function

Detailed description

Clinical response, Subjective cognitive performance, Autobiographical memory function, Executive cognitive function, Separate cognitive domains, Patient satisfaction, Pre-treatment anxiety, Reorientation time, Seizure quality, Brain memory networks

Interventions

DRUGFLUMAZENIL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective cognitive function	—

Secondary

Measure	Time frame
Clinical response, Subjective cognitive performance, Autobiographical memory function, Executive cognitive function, Separate cognitive domains, Patient satisfaction, Pre-treatment anxiety, Reorientation time, Seizure quality, Brain memory networks	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026